D espite a relative reduction in the hospitalization rate of heart failure (HF), the actual number of HF hospitalizations remains over 1 million annually. This figure is expected to significantly worsen with the aging US population and the growing HF prevalence. Over 80% of patients who are hospitalized are initially seen in the emergency department (ED).
GUIDED-HF Design and Rationale
disposition decisions for those who present with acute heart failure (AHF) rest largely with ED providers, the ED has a central role in avoiding unnecessary hospitalizations. However, because patients with HF are older, with significant comorbidities and polypharmacy, the high rate of ED admission may be driven by factors other than acuity-a circumstance compounded in settings where socioeconomic challenges exist.
To optimize care and reduce ED and hospital revisits, there has been significant emphasis on improving transitions at the time of hospital discharge for patients with HF. Such efforts have been almost exclusively directed at hospitalized patients; individuals with AHF who are discharged from the ED are generally not included in these transitional care initiatives. Ensuring optimal care transitions for discharged ED patients with AHF is a critical unmet need. Data show that patients with AHF discharged from the ED receive suboptimal guideline-directed medical therapy, suggesting that interventions to improve AHF transitions are needed in the ED setting.
2 This is particularly true for patients in resource limited settings, many of whom have vulnerable characteristics. Although the uninsured are more likely to be discharged, when admitted to the hospital, they consume a disproportionately larger amount of hospital resources. 1 Limited outpatient resources may place a burden on inpatient providers to ensure that a comprehensive work-up is performed before discharge. Admission for this specific reason may not be ideal. However, when patients with HF are discharged from the ED with a poor or absent transitional care plan, emergency physicians may be the sole or primary providers delivering treatment, precluding initiation of a more holistic management plan.
Transition of Care Initiatives
There have been mixed results with existing transition of care initiatives designed to shift hospitalized patients to the outpatient setting with the goals of reducing mortality and 30-day return visits, while improving quality of life indicators. 3, 4 Many have been developed within broader quality improvement portfolios by sponsoring professional organizations, widely adopted, and resulted in end-user insight into what is effective what does and does not work. 5 For instance, 599 hospitals participating in the American College of Cardiology-sponsored Hospital to Home Program were surveyed to evaluate the programmatic strategies most effective at reducing hospital risk-standardized 30-day readmission rates for HF. Despite presumed effectiveness, factors such as arranging follow-up visits before discharge were found to contribute only modest reductions of the riskadjusted standardized 30-day readmission rates, with the average reduction of less than half a percentage point. 6 Get With The Guidelines-Heart Failure (GWTG:HF), an American Heart Association-sponsored program designed to measure and implement evidence-based HF care, is one of the most successful transition of care endeavors. As of July 2016, over 600 hospitals and 1.3 million patients have participated in GWTG:HF. One goal of the program is to reduce sex-and race/ethnicity-related disparities in health care. Hospitals enrolled in GWTG:HF have demonstrated better processes of care, reductions in quality of care and outcome disparities, and lower 30-day readmission rates when compared with nonparticipating hospitals. [7] [8] [9] Because these barriers disproportionally affect vulnerable populations, including those with low health literacy, low socioeconomic status, the uninsured, and minorities, these interventions may have greater impact in such patients and thereby reduce disparities in ED revisits and hospitalizations. 10, 11 Unfortunately, the GWTG:HF program is currently designed for hospitalized patients and focuses on optimizing inpatient postdischarge care. Tailoring this evidence-based intervention to target patients who are missed in current GWTG:HF programs, namely the 15% to 20% of patients with AHF who are discharged directly from the ED or after ED-based observation, would address a critical unmet need.
Self-Care in Patients With AHF
A key component of transition initiatives is facilitating selfcare management. Self-care has been defined as a naturalistic decision-making process related to patient behavioral choices that maintain physiological stability and the response to symptoms when they occur. 12 In HF, self-care maintenance involves adherence to medications, a low sodium diet and exercise. Selfcare management requires patients to monitor their symptoms (eg, edema), recognize a change, and respond with appropriate interventions (eg, take additional dose of diuretic and call their caregiver). 12 Much of the experience in self-management comes from subjects with chronic HF. A recent comprehensive review of self-care in patients with HF concluded that self-management reduced the time to HF-related hospitalization, the combined end point of HF-related hospitalization or all-cause mortality, and improved 12-month HF-related quality of life. 13 In patients <65 years old, self-care management was associated with a reduction of HF-related hospital days. However, in a subset of patients with moderate to severe depression, a self-care strategy was associated with reduced survival. 13 In addition, self-care strategies did not impact all-cause hospitalization, quality of life, and mortality. ED patients with AHF who are discharged after a brief period of observation have similar or even greater needs. However, self-care initiatives for AHF have not been well studied in this cohort.
Safe Transition to the Outpatient Setting From the ED: An Unmet Need
Patients who follow-up with their provider soon after discharge are much less likely to be readmitted or experience an adverse event. 14, 15 However, follow-up may occur in as few as 50% of patients within 30 days of ED discharge. 15 Inadequate or poorly understood discharge instructions and systems issues are responsible for a large proportion of these missed followup opportunities. 16 Vulnerable AHF populations, including those with low health literacy, low socioeconomic status, the uninsured, and minorities, are disproportionally affected by an ineffective transition strategy. Because vulnerable patients are highly represented in ED AHF populations, we hypothesize that the interventions in this cohort may have even greater impact in reducing disparities in ED revisits and hospitalizations. 10, 11 A carefully designed randomized trial comparing usual care with our GUIDED-HF transition strategy (Get With the Guidelines in Emergency Department Patients With Heart Failure) (Figure 1 ) in patients with AHF discharged from the ED would bridge this critical evidence gap. This study will provide prospective, randomized trial data to support how EDs should manage lower risk patients with AHF. It will also evaluate the effectiveness of interventions to reduce health disparities in cardiovascular disease.
Design of the GUIDED-HF Study
GUIDED-HF is a multicenter randomized trial of a transition intervention compared with standard ED discharge in patients with AHF who are discharged either directly from the ED or after a brief period of ED-based observation. The conceptual model ( Figure 2 ) for the study was based on overcoming barriers to self-care and improving transitions from the ED to outpatient setting to improve our proposed outcomes. This conceptual model aims to improve on these outcomes by using (1) services, such as emergency medicine and HF providers and guideline-recommended HF therapy and (2) mediators, such as using the communication skills and medical knowledge of the study team and providers.
The overall study design is described in Figure 1 . A total of ≤700 patients at 11 sites will be enrolled over 3 years. All patients in GUIDED-HF will provide written informed consent. The study was designed and led by a steering committee consisting of physician scientists, patients, caregivers, and American Heart Association representatives. GUIDED-HF is funded by the Patient-Centered Outcome Research Institute and, as such, a cornerstone of protocol development involved stakeholder engagement. In GUIDED-HF, this included direct, face-to-face solicitation of input from chronic HF patients and their caregivers using an established Community Engagement Studio at Vanderbilt University and outreach to the broader HF population through the American Heart Association Virtual Online Community of Patients, Caretakers, and Stakeholders. 17 For the latter, digital channels on Facebook and Twitter were used to host a "Highlight on HF" week, where >1400 patients with HF provided feedback informing the study design, plan for implementation, and ultimately dissemination of study findings. This feedback was collated and had significant influence on our primary and secondary aims and the structure of the study and its committees and coordinating centers ( Figure  3 ). In addition, patients with HF are active participants in monthly study calls and article preparation.
Study Populations
Patients who present to the ED with signs or symptoms of AHF will be screened. Eligibility criteria are (1) ED physician AHF diagnosis, (2) plan is discharge either directly or after a brief period of ED-based observation, and (3) patients who will not have difficulties complying with the protocol because of psychiatric disease, dementia, or distance from the enrolling institution, making the home visit problematic. Specific inclusion and exclusion criteria (Table 1) were chosen to identify a low-risk patient cohort able to engage in our comprehensive outpatient intervention, including a home visit shortly after discharge.
Although the ED diagnosis may disagree with an inpatient diagnosis in 10% to 15% of cases, 18 our design is pragmatic. We are interested in enrolling patients diagnosed with and treated for AHF in the ED, not a cohort of patients where AHF was confirmed after hospital admission. We have excluded complex and high-risk patients, such as those with a systolic BP <100 mm Hg, acute coronary syndrome based on typical signs and symptoms and ECG changes or cardiac troponin elevations, as well as those receiving an inotrope infusion as an outpatient. These would be atypical features among patients discharged from the ED or ED-based observation. We also excluded patients with no previous history of HF because these patients require extensive evaluations outside the context of the current proposal. In essence, we aim to enroll a patient cohort with established HF where important aspects of our intervention, such as initiation or titration of guidelinedirected medical therapy, can be quantified and implemented.
Study Treatment
Patients are block randomized to either the GUIDED-HF strategy or standard discharge by site. Patients in the GUIDED arm receive a tailored discharge plan via the study team, based on their identified barriers to outpatient management and associated guideline-based interventions. As with all Patient-Centered Outcome Research Institute-funded studies, GUIDED-HF is inherently geared toward patient preferences, that is, working with participants to define the care components of most importance to them, devise an intelligible, acceptable, and achievable care plan, and assess the impact of treatment on patient-centered outcomes (defined below). The study team at each site is afforded flexibility to execute this tailored discharge plan based on the patient's needs and their available study personnel. All staff carrying out the home visits have been trained by study personnel with HF expertise. The investigators felt that this was an important pragmatic feature of the trial and will afford rapid dissemination after study completion. These study personnel focus on 4 main areas as part of the intervention.
1. Disease Education: We have previously used the short literacy screen to identify literacy barriers to understanding discharge and medication instructions in ED patients with AHF. 19 For those patients with either self-reported difficulty or a short literacy screen score <12, the study team will use our medication regimen visual aid and teach back to confirm comprehension of all instructions. 19, 20 Those patients without literacy deficiencies will receive standard HF disease education using an accepted HF disease module. 21 2. Lifestyle Interventions: To maintain consistency with GWTG:HF, smokers receive smoking cessation information. The study team also provides dietary education based on the HF disease education module, emphasizing low sodium intake. Patients are instructed to track their daily weights with provision of a scale as needed.
Patients are instructed to contact their physician when HF symptoms arise such as weight gain, swelling, and dyspnea.
Guideline Recommendations for Medications and
Device Referral: Patients' HF characteristics (ejection fraction, renal function, blood pressure, and heart rate) and GWTG:HF recommendations determine the need for prescriptions for guideline-directed medical therapy, including angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, β-blockers, aldosterone antagonists, anticoagulants, and referral for pacemaker/ defibrillator consideration. The study team works with the patient to ensure affordable and accessible prescriptions (using generic substitutions and nearby pharmacies where low-cost monthly prescriptions are available when possible). For patients without access to a pharmacy, the study team may pick up the prescribed medications for the patient before the study-specific home visit, arrange for a caregiver to assist, have the medications mailed to the patient, or arrange for hospital supplied bridge dosing. 4. Outpatient Follow-Up Appointment: The study team works with the patient's provider or arranges for a new provider, to ensure a follow-up appointment within 7 to 10 days of ED discharge. For patients without a physician, this will be with an HF provider at each of the study sites. The study team also visits the patient within 48 hours of discharge to assess their home environment and further tailor the patient's plan as needed. Potential areas of discussion and intervention include healthy eating habits (eg, avoiding salt and frozen vegetables), setting up a scale for recording daily weights, showing the patient and caregiver on how to use a weekly medication organizer, and reinforcing early signs and symptoms of worsening HF. After the home visit, the study team performs coaching calls twice per month to answer any questions and assist with further needs and outpatient follow-up. Patients assigned to the standard discharge arm receive ED or ED-based observation discharge instructions as per routine institutional practice. Similar to the GUIDED-HF arm, the study team also assists with facilitating a follow-up appointment within 7 to 10 days of discharge. However, these patients do not receive a home visit or coaching calls. Although the discharge instructions delivered in the standard arm are determined by local practice, we have provided the sites with an outline of what structured standard practice should include. The completeness of this type of instruction and the degree of knowledge retention is followed as part of the GUIDED data collection and is a subject of an ongoing scrutiny. 22 Although we provide recommendations for structuring ED discharge instructions and follow-up in the standard care arm, the rigorous ED evaluation and discharge instructions, home visit, and coaching calls only occur in the GUIDED arm. Although there could be a small amount of contamination in the standard care arm, our structured discharge process aims to minimize this.
End Points
The primary outcome is a 90-day composite end point of (1) time to ED revisit or hospital admission for AHF, (2) a clinic visit for AHF resulting in intravenous diuretic administration, or (3) cardiovascular death ( Table 2 ). The 90-day end point was chosen predominantly to ensure sustainability of our interventions and to include both safety and efficacy. However, an important secondary end point will be the impact of our intervention at 30 days, which is more temporally related to the ED visit. Data on the number, timing, and reasons for admissions, ED visits, hospital procedures, and study-related home visits are abstracted from patients' records and by telephone follow-up, with recording on standardized data collection forms. Death is determined by the documentation in the medical record, caregiver reports on follow-up, and by query of the social security death index 6 months after the index ED visit. A clinical events committee is available to review the medical records in patients who have experienced events to determine whether the event qualifies as a primary end point. Information which could unblind the clinical events committee to the treatment group is redacted from the medical record. Secondary outcomes captured by phone follow-up at 30 and 90 days include the Kansas City Cardiomyopathy Questionnaire (measuring quality of life; ranged 0-100), the Dutch HF Knowledge Scale, 23 and estimates of out-of-pocket expenses because of hospitalizations, ED/office visits, diagnostic and laboratory testing, and medications. We also evaluate medication adherence using the Adherence to Refills and Medications Scale 24 and reasons for inability to adhere, including medication costs. Finally, patient satisfaction at the time of ED discharge is measured via a Likert scale, and the National Institutes of Health Patient-Reported Outcomes Measurement Information System tools are used to capture potential effect modification by depression and anxiety. To minimize bias by study personnel who are ascertaining follow-up, we require each site to conduct phone follow-ups using standardized interviews conducted by members of the study team blinded to treatment assignment. This key characteristic of the study will be monitored, and corrective action plans will be instituted if any sites do not adhere to enrollment criteria, exhibit bias in selection of patients for enrollment, or do not adhere to the study protocol. We acknowledge that information may be transmitted during the follow-up phone calls that may suggest to the blinded site personnel that a subject is in either the standard or GUIDED arm.
In addition, to determine the sustainability of our intervention, we collect 180-day data on our primary and select secondary outcomes. A key challenge of our design is ensuring adherence to the GUIDED-HF interventions and follow-up for those patients enrolled. All sites have extensive previous experience following patients from ED enrollment ≤180 days of follow-up and beyond. Our sites formal follow-up process includes a medical record review, at least 3 calls to the patient and the alternative phone number provided, and sending a certified letter. In our previous ED-based studies, we have completed follow-up in >95% of enrolled subjects. 25, 26 
Safety Measures
Our safety end points include all-cause 90-day events (1) ED revisits, (2) hospital admissions, and (3) death. An independent data safety and monitoring board oversees the safety of patients throughout the trial. During the planning phase of GUIDED-HF, the data safety and monitoring board met to approve the study protocol and approve the specific monitoring plan, including the monitoring frequency, data to be reviewed, and statistical procedures.
Statistical Analysis and Power Calculations
We are using a time-to-event (ie, survival) analysis to characterize the observed patterns while properly accounting for loss to follow-up, dropout, and other types of censoring events. Non-cardiovascular death will be treated as a censoring event for the primary outcome but will be followed as part of our safety end point. Because the impact of our tailored intervention will depend on the participant's clinical profile, the model will adjust for the following covariates: age, sex, race, previous ejection fraction, baseline Kansas City Cardiomyopathy Questionnaire scores, AHF therapy during the ED stay, and ED testing results, including blood urea nitrogen and creatinine, systolic blood pressure, natriuretic peptide, and troponin concentrations. This is a standard ED data collected in over 95% of patients in our previous studies. [25] [26] [27] The secondary outcomes are longitudinally measured patient-reported measures, including Kansas City Cardiomyopathy Questionnaire and the Dutch HF score, which will be collected at the time of discharge (baseline), and again at 30 and 90 days after discharge. We will track total out-of-pocket charges related to hospitalizations and ED/office visits, diagnostic and laboratory testing, and medications as reported by patient at their 30-and 90-day follow-up.
The planned sample size of 700 subjects, equally distributed across the 2 intervention arms stratified by site and vulnerable and nonvulnerable populations, will provide excellent precision to address our primary and secondary outcomes with a 2-sided type I error rate of 5%. The power calculation is based on standard methods for a proportional hazards model. 28 On the basis of our previous ED cohort studies and existing literature, 26, [29] [30] [31] we expect, in the usual care arm, event rates of 26% and 62% for our primary outcome at 30 and 90 days, and censoring rates of 2% at 30 days and 4% at 90 days. For testing the intervention effects in reducing disparities, we assume 70% of the discharged patients will have a vulnerable characteristic (low socioeconomic status, minority, uninsured, and low health literacy). Using the 90-day information, the proposed sample size will offer 80% power to detect a hazard ratio of 0.55=1/1.82 for the interaction term, which corresponds to 45% reduction of disparity in relative risk between vulnerable and nonvulnerable population.
Conclusions
Transitions initiatives in patients with AHF have historically not included patients discharged from the ED or ED-based observation. Self-care is a cornerstone of successful chronic disease management. Addressing self-care may be even more important in patients who are not hospitalized. ED patients have a high proportion of vulnerable characteristics and known disparities in outcomes. GUIDED-HF will test a novel approach to transitional care, using an early home visit combined with close outpatient follow-up and subsequent coaching calls to avoid unnecessary ED and hospital admissions. Further, the flexibility in conducting home visits and coaching calls facilitates the local implementation of the GUIDED strategy using a variety of healthcare providers. Ultimately, if GUIDED-HF proves to be successful, its impact will hinge on successful integration of the GUIDED-HF strategy into clinical practice guidelines and quality improvement initiatives.
Clinical Perspective
Ensuring optimal care transitions for patients with acute heart failure who are discharged from the emergency department is a critical unmet need. These patients often receive suboptimal guideline-directed medical therapy and early follow-up, suggesting that the interventions to improve acute heart failure transitions are needed in the emergency department setting. The GUIDED-HF study seeks to optimize this transition by using practical and relevant protocols to reinforce self-care strategies.
Translational Outlook
Successful integration of the GUIDED-HF strategy into clinical practice guidelines and quality improvement initiatives will be a measure of success for this program. We hypothesize that using an early home visit combined with close outpatient follow-up and subsequent coaching calls will avoid unnecessary ED and hospital admissions. To translate the GUIDED-HF strategy to the care of individual patients beyond the study period, GUIDED-HF allows for flexibility in conducting home visits and coaching calls. This flexibility facilitates the local implementation of the GUIDED strategy using a variety of healthcare providers and enhances the sustainability of this initiative after the study has been completed.
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